Treatment of Moderate to Severe Facial Acne Vulgaris
Launched by WARNER CHILCOTT · Jan 25, 2008
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be between 12 and 45 years of age.
- • Has a diagnosis of moderate to severe facial acne vulgaris with no more than two nodules on the face
- Exclusion Criteria:
- • Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.
- • Has a history of pseudomembranous colitis or antibiotic-associated colitis.
- • Has a history of hepatitis or liver damage or renal impairment.
About Warner Chilcott
Warner Chilcott is a leading pharmaceutical company specializing in the development and commercialization of innovative prescription products in the fields of women's health, urology, and dermatology. With a commitment to enhancing patient outcomes, Warner Chilcott focuses on delivering high-quality medications that meet the evolving needs of healthcare providers and patients. The company is dedicated to rigorous clinical research and adherence to regulatory standards, ensuring the safety and efficacy of its therapies. Through strategic partnerships and a robust pipeline, Warner Chilcott continues to advance healthcare solutions that improve the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Austin, Texas, United States
Encino, California, United States
Fremont, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Denver, Colorado, United States
Miami, Florida, United States
Newnan, Georgia, United States
Snellville, Georgia, United States
Louisville, Kentucky, United States
Clinton Township, Michigan, United States
Albuquerque, New Mexico, United States
Rochester, New York, United States
Cincinnati, Ohio, United States
Broomall, Pennsylvania, United States
Fort Washington, Pennsylvania, United States
College Station, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Spokane, Washington, United States
Patients applied
Trial Officials
Angelo Secci, MD
Study Director
Warner Chilcott
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials